Search Results for: Research
Make your Milk Powder as Proactive to Health as Your Consumers Are!
Consumers show a greater interest in functional products and ingredient claims than ever before, as they seek out products that offer a convenient health boost.
62% of consumers in Asia-Pacific identify “Overall Health” as the critical concern resulting from COVID-19.
Fortification is an opportunity for differentiation
Learn more about the most important vitamin consumers may never have heard of!
Adding vitamin K2 to milk powder ensures calcium is guided to building bone and diverted away from soft tissue
MenaQ7®️ K2 is clinically proven to support the needs of healthy bones in children.
Kids – Growing Strong Bones
Clinical research show children taking 45 mcg of MenaQ7® resulted in improved vitamin K status and stronger, denser bones. Milk powder as a delvery format represent an opportunity to mitigate deficency and to support children growing strong bones.
Supporting Bone Health in
Postmenopausal Women
Maintaining the best possible cardiovascular and bone health are two of the most critical areas allowing women to age in a healthy way.
MenaQ7® is the only Vitamin K2 clinically proven to protect bone strength and density in postmenopausal women.
MenaQ7® K2 is clinically proven to support bone and heart health in adults.
MenaQ7® K2 is clinically proven to support bone and heart health in adults.
Vitamin K2 is Key for Healthy Ageing
Being fearful for poor bone and cardiovascular health can be a hindrance for the growing population of senior citizens to engage in activities, travel, and exercise
Calcification is believed to be an unfortunate result of aging, but studies show that arterial calcification is, in fact, an actively regulated process.
MenaQ7® Vitamin K2 taken daily is not only shown to inhibit age-related arterial stiffening but improve vascular elasticity.
Knapen MHJ et al. Thrombosis and Haemostasis, 2015; 19;113(5).
The Only Clinically Proven K2 now available in milk powders!
Providing solutions to make Vitamin K2 available in a broader range of finished product dose forms is at the heart of the NattoPharma R&D team.
Vitamin K2 creates synergies for health and is the better together vitamin to supercharge other vital nutrients like vitamin D, Calcium and Omega3 to strengthen solid foundational health across all stages in life.
Adding MenaQ7® K2 to milk powders will ensure calcium is optimally trapped to the bone matrix and away from arteries where it can do harm.
Learn how K2 has Better Together Synergies with vitamin D for bone and cardiovascular health www.menaq7.com/bettertogether
You Have The Questions,
We Have The Answers
Is MenaQ7 compatible in milk powder?
MenaQ7® Vitamin K2 is now offered in a solution developed specifically for milk powder compatibility
- Stability protocol available
- No flavour or odour to interfere with the finished product
Are consumers interested in K2?
NattoPharma has educated the health supplement industry and has all the tools you need to tell the K2 story to consumers, we will show you how!
How do I know vitamin K2 will be bioavailable from dairy?
Study show drinkable yogurt fortified with MenaQ7 Vitamin K2 provided the same bioavailability as supplements.
What about safety and efficacy?
MenaQ7 is proven safe and efficacious in 20+ clinical trials.
Book a K2 Meeting in Your Calendar Today
Copyright Ⓒ 2015 MenaQ7. All Rights Reserved. MenaQ7 Vitamin K2 is a trademark of MattoPharma ASA.
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation. Heart Health ranks as one of the top 3 reasons respondents use dietary supplements. At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering … Continue reading Consumer Survey Shows Interest in Supplements for Artery Health
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation.
Heart Health ranks as one of the top 3 reasons respondents use dietary supplements.
At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering three primary questions:
1. How concerned are people with the health of their heart?
2. Do they believe that hard arteries are a problem that is associated with poor heart health?
3. How willing would they be to take a supplement to improve the health of their heart by preventing (and even reversing) the hardening of their arteries?
Key Findings: Of the 380 individuals surveyed:
• 87% currently take vitamins or supplements to improve their health.
• 25% identify themselves as having a condition associated with heart disease; 40% have someone in their immediate family with a condition associated with heart disease.
• 35% are very concerned that hardening of the arteries will have a negative impact on their heart health.
• 67% of those surveyed (n = 380) would take a supplement shown to stop hardening of the arteries if the supplement carried no side effects and is priced about the same as other heart health supplements.
Bone and Heart Health are the top reasons customers supplement (reason 2 and 3, respectively). When asked how concerned they were about their heart health on a scale of 1-7, 62% rated their level of concern as 5 or greater (38% rated their level of concern 6 or greater).
Of those who indicated that they or their family member currently has a heart condition (n=232),
• 84% are currently taking a prescription medicine (55% would consider taking a prescription)
• 44% are currently taking a supplement (59% would consider taking a supplement)
Of those who indicated that they currently do not have a heart condition (n=148), for those surveyed between 30 and 40 years old, supplements would be their No. 1 action if they developed heart disease.
“Just over one-third of survey participants ranked ‘hardening of the arteries’ as one of the top 3 risk factors associated with heart disease. This is a concern with growing awareness with Americans, but a natural solution to address this concern was not previously available,” said Eric Anderson, senior vice president of global sales and marketing with ex-NattoPharma, exclusive global supplier of MenaQ7® Vitamin K2 as MK-7. “However, our clinical trials have shown that MenaQ7 addresses 2 of the top 3 reasons that health-minded consumers supplement: MenaQ7 not only protects against age-related hardening of the arteries and regressed arterial stiffening, but it also has been shown to improve bone mineral density and strength.”
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos. Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”. Biolab … Continue reading Product Launch in Brazil
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos.
Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”.
Biolab Farmacêutica is one of the largest pharmaceutical companies in Brazil, and the No. 1 pharmaceutical company for cardiology prescriptions. More than 600 cardiologists attended the event hosted by Biolab, and NattoPharma, world leaders in Vitamin K2 research and development, had representatives on hand to explain the substantial body of science supporting MenaQ7 Vitamin K2 as MK-7, specifically the cardiovascular benefits.
“It was our pleasure to participate in the Brazilian launch of Doiska MenaQ7, and a privilege to present our clinical substantiation to more than 600 engaged cardiologists in São Paulo,” says Dr. Hogne Vik, ex-NattoPharma Chief Medical Officer, who presented alongside respected cardiologist Prof. Dr. Francisco Fonseca.
According to Flavio Zemella, Biolab Marketing Director, the symposium was very successful and physicians are excited about Doiska MenaQ7® arrival in the pharmacies, expected by beginning of August this year. “We are confident the partnership between ex-NattoPharma and Biolab will be very fruitful as we foresee the product will benefit thousands of Brazilians across the country.”
Supporting Mothers for Healthy Babies
Pregnancy is a time of extraordinary change and the WHO estimates 20-30% of pregnant women suffer from some kind of vitamin deficiency. Post-natal supplements are important for many women during this period of their lives to ensure not only their health, but their babies as well.
In particular, pregnant women are advised to increase their calcium levels to support the growing babies’ bone and teeth – and to maintain the mothers own bone mass, which is depleted during pregnancy and nursing.
Research shows that women’s bone metabolic status significantly changes over the period between pregnancy and during nursing [6], and as much as 50% of newborns are K deficient. Incorporating Vitamins K2 with D3 in post-natal supplements would benefit both mother and child through their combined optimization of calcium.
[6] Miyamoto T et al. Sci Rep. 2019 May 13;9(1):6787.
MenaQ7 study show
45 mcg per day of vitamin K2 was shown to support the needs of healthy bones in children
Growing Strong Bones
Childhood is the most essential period for developing and building healthy bone mass.
However, research shows children have 8 to 10 times higher levels of inactive osteocalcin, which means they are not optimally building the bone mass they require during this period.[3]
In turn, today we see an increase in low-energy fractures in children. Thankfully there is a way to mitigate this situation.
Studies show that children who have optimal levels of Vitamins K2 and D3 have fewer bone fractures than children with lower status of these two vitamins. [4,5]
MenaQ7® is the only Vitamin K2 on the market proven to benefit bone health in children.
[3] Theuwissen E et al. Food & Function. 2013;5(2):229-34
[4] Popko J et al. Nutrients. 2018 Jun 6;10(6):734.
[5] Karpiński M et al. J Am Coll Nutr. 2017 Jan;36(1):64-71
Exciting new evidence confirming K2 as MK-7 modulates immune and inflammatory biomarkers. Journal of Medicinal Food has published a new study that successfully tested and confirmed the role of vitamin K2 as MK-7 (menaquinone-7; MenaQ7® provided by ex-NattoPharma) in modulation of the immune and inflammatory biomarkers. The study, “Inhibition of TNF-a, IL-1a, and … Continue reading MenaQ7® K2 Study Validates Inflammation Benefits
Exciting new evidence confirming K2 as MK-7 modulates immune and inflammatory biomarkers.
Journal of Medicinal Food has published a new study that successfully tested and confirmed the role of vitamin K2 as MK-7 (menaquinone-7; MenaQ7® provided by ex-NattoPharma) in modulation of the immune and inflammatory biomarkers.
The study, “Inhibition of TNF-a, IL-1a, and IL-1b by Pretreatment of Human Monocyte-Derived Macrophages with Menaquinone-7 and Cell Activation with TLR Agonists In Vitro,” is significant because it confirms another mechanism by which vitamin K2 supports cardiovascular health by impact markers of inflammation.
“Chronic inflammation is considered an underlying pathology of many diseases that remain poorly understood and treated,” the researchers wrote. “Cardiovascular disease (CVD), a leading cause of mortality in the world, is not only considered as a disorder of lipid accumulation, but also as a disease characterized by low-grade inflammation of the endothelial cells and an inappropriate healing response of the vascular lining.”
The commonly recognized function of vitamin K is a cofactor for c-glutamyl carboxylase, an endoplasmic enzyme involved in the posttranslational carboxylation (activation) of proteins with glutamic acid (Glu) residues into c-carboxyglutamate (Gla). With the carboxylation of glutamic acid residues on the protein substrate, a negative chemical group is formed that attracts and binds positively charged calcium cation. Vitamin K2, in particular, is responsible for carboxylation and activation of osteocalcin, which is essential for physiology of bone-building cells, osteoblasts. Vitamin K2 helps in carboxylation and activation of another protein besides osteocalcin, that is, matrix GLA protein (MGP), important for elasticity and prevention of calcification of blood vessels.
To that end, researchers evaluated high-purity natural vitamin K2 (98.4% menaquinone-7, MK-7, as MenaQ7) in vitro for its potential to inhibit gene expression and production of pro-inflammatory markers by human monocyte-derived macrophages (hMDMs) from two sources (hMDMs and THP-1).
The anti-inflammatory mechanism of vitamin K2
The results showed that the MK-7 form of vitamin K2 is able to dose- dependently inhibit TNF-a, IL-1a, and IL-1b gene expression and protein production by healthy hMDMs in vitro. According to the researchers, “In view of these encouraging findings on the anti-inflammatory properties of MK-7, we plan to test additional biomarkers of immune and inflammatory response in this form of vitamin K2 in vitro. This work may elucidate the anti-inflammatory mechanism of vitamin K2 and establish the potential biomarker targets in clinical testing of the role of MK-7 in the cardiovascular health as well as other chronic degenerative conditions.”
“All of the work showing the efficacy of MK-7 inhibiting cardiovascular and soft tissue calcification is recognized to the extent that scientific experts continue to explore new benefits and mechanisms,” says Hogne Vik, ex-NattoPharma chief medical officer. “These findings are very exciting and promising, and we are thrilled that we could offer the research team our vitamin K2 material – providing another piece of evidence that MenaQ7 is a clinically validated ingredient delivering true benefits for human health.”
Reference:
Pan MH, Maresz K, Lee PS, Wu JC, Ho CT, Popko J, Mehta DS, Stohs S??J, Badmaev V. Inhibition of TNF-a, IL-1a, and IL-1b by Pretreatment of Human Monocyte-Derived Macrophages with Menaquinone-7 and Cell Activation with TLR Agonists In Vitro. J Med Food.2016 Jul;19(7):663-9.